Advisory Research’s Cue Biopharma CUE Stock Holding History

Advisory Research’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$59.1K	Hold	8,574	–	–	0.01%	137
2025 Q4	$78.6K	Hold	8,574	–	–	0.01%	142
2025 Q3	$185K	Hold	8,574	–	–	0.02%	145
2025 Q2	$176K	Hold	8,574	–	–	0.03%	139
2025 Q1	$234K	Hold	8,574	–	–	0.04%	142
2024 Q4	$280K	Hold	8,574	–	–	0.05%	143
2024 Q3	$195K	Hold	8,574	–	–	0.03%	153
2024 Q2	$319K	Hold	8,574	–	–	0.06%	146
2024 Q1	$486K	Hold	8,574	–	–	0.1%	131
2023 Q4	$679K	Hold	8,574	–	–	0.1%	202
2023 Q3	$592K	Hold	8,574	–	–	0.08%	253
2023 Q2	$939K	Hold	8,574	–	–	0.12%	211
2023 Q1	$918K	Hold	8,574	–	–	0.15%	167
2022 Q4	$733K	Hold	8,574	–	–	0.07%	195
2022 Q3	$574K	Hold	8,574	–	–	0.06%	222
2022 Q2	$640K	Hold	8,574	–	–	0.06%	196
2022 Q1	$1.25M	Hold	8,574	–	–	0.1%	163
2021 Q4	$2.91M	Buy	8,574 +41	+0.5%	+$15.9K	0.23%	79
2021 Q3	$3.73M	Hold	8,533	–	–	0.24%	98
2021 Q2	$2.98M	Hold	8,533	–	–	0.2%	109
2021 Q1	$3.12M	Buy	+8,533	New	+$3.51M	0.22%	104

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

GWMR

GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

AWM

Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Advisory Research's CUE Position: Q1 2026 in Review

Advisory Research held its Cue Biopharma (CUE) position steady in Q1 2026 at 8,574 shares worth $59.1K. The position accounts for 0.01% of the portfolio, ranked #137.

Advisory Research first reported a position in CUE in Q1 2021 and has held it in 21 quarters since. The position peaked at $3.73M in Q3 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

Advisory Research held 8,574 shares of Cue Biopharma worth $59.1K as of Q1 2026.
Advisory Research left its Cue Biopharma share count unchanged in Q1 2026.
Cue Biopharma made up 0.01% of Advisory Research's portfolio in Q1 2026, its #137 holding.
Advisory Research first reported a position in Cue Biopharma in Q1 2021 and has held it in 21 quarters since.
Advisory Research's Cue Biopharma position peaked at $3.73M in Q3 2021.
55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Advisory Research's 13F filing for Q1 2026, filed 14 May 2026.